Cash Injection Fuels Viela Bio's NMOSD FDA Filing

New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.

Rocket
Do we have lift off? New cash has the potential to propel inebilizumab into orbit • Source: Shutterstock

The MedImmune LLC spin-out Viela Bio Inc. has raised $75m in a series B financing that it will use to push forward US Food and Drug Administration approval of its monoclonal antibody (MAb) inebilizumab for the rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD).

Viela presented pivotal data from a Phase IIb study for inebilizumab in January 2019, when analysis demonstrated a 77% reduction...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip